POSTER: MPN-056 Fedratinib May Be the First Choice for Patients Affected by Myelofibrosis and Concurrent Lymphoproliferative Disorder or Developed After Another JAKi Therapy
- Resource Type
- Abstract
- Source
- In
Clinical Lymphoma, Myeloma and Leukemia September 2023 23 Supplement 1:S196-S196 - Subject
- Language
- ISSN
- 2152-2650